HOME
SEARCH
RSS FEED
SUBSCRIBE
Fibroblast Cell Lines Homozygous for Glucocerebrosidase (GBA1) Mutation N370S for the Screening of Small Molecules for Gaucher Disease Treatment
Case ID:
TAB-3636
Web Published:
12/6/2022
Description:
This technology includes two human fibroblast cell lines be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. Inventors have collected fibroblasts from various patients, including those with homozygous mutation N370S. This is the most common mutation found in Gaucher patients and is found in the non-neuronopathic form of the disease.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/Fibroblast_Cell_Lines_Homozygous_for _Glucocerebrosidase_(GBA1)_Mutation_N370S_for_the_Screening_of_Small_Molecul es_for_Gaucher_Disease_Treatment
Category(s):
Research Equipment
Research Materials
Ophthalmology
Endocrinology
Cardiology
Infectious Disease
Therapeutics
Dental
Oncology
Bookmark this page
Download as PDF
For Information, Contact:
Eggerton Campbell
Licensing And Patenting Manager
NIH Technology Transfer
301-402-1648
eggerton.campbell@nih.gov
Inventors:
Barbara Stubblefield
Ellen Sidransky
Keywords:
Cell
Fibroblast
GBA1
GLUCOCEREBROSIDASE
HOMOZYGOUS
Lines
Listed LPM Vepa as of 4/15/2015
MUTATION
N370S
Post LPM Assignment Set 20150420
Pre LPM working set 20150418
VPXXXX
WIXXXX
WKXXXX
XHXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum